Stocklytics Platform
Asset logo for symbol RGNX
REGENXBIO
RGNX52
$12.58arrow_drop_down2.10%-$0.27
Asset logo for symbol RGNX
RGNX52

$12.58

arrow_drop_down2.10%

Performance History

Chart placeholder
Key Stats
Open$12.85
Prev. Close$12.85
EPS-5.87
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range12.38
13.14
52 Week Range10.49
28.80
Ratios
EPS-5.87

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$857.46
Perf. (24h)
arrow_drop_up1.00%$8.56
Market Cap$764.35B
Price$565.33
Perf. (24h)
arrow_drop_up0.17%$0.98
Market Cap$519.41B
Price$154.69
Perf. (24h)
arrow_drop_down0.46%-$0.73
Market Cap$374.04B
Price$125.77
Perf. (24h)
arrow_drop_up1.22%$1.52
Market Cap$314.70B

About REGENXBIO (RGNX)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Kenneth T. Mills
Headquarters
Rockville
Employees
401
Exchange
NASDAQ
add REGENXBIO  to watchlist

Keep an eye on REGENXBIO

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is REGENXBIO 's (RGNX) price per share?

The current price per share for REGENXBIO (RGNX) is $12.58. The stock has seen a price change of -$0.27 recently, indicating a -2.1% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for REGENXBIO (RGNX)?

For REGENXBIO (RGNX), the 52-week high is $28.8, which is 128.93% from the current price. The 52-week low is $10.49, the current price is 19.92% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is REGENXBIO (RGNX) a growth stock?

REGENXBIO (RGNX) has shown an average price growth of 0.41% over the past three years. It has received a score of 24 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying REGENXBIO as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is REGENXBIO (RGNX) stock price performance year to date (YTD)?

As of the latest data, REGENXBIO (RGNX) has a year-to-date price change of -31.41%. Over the past month, the stock has experienced a price change of 5.89%. Over the last three months, the change has been -19.82%. Over the past six months, the figure is -8.24%. Looking at a longer horizon, the five-year price change stands at -74.39%.

help
Is REGENXBIO (RGNX) a profitable company?

REGENXBIO (RGNX) has a net income of -$263.49M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 39.57% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -395.35% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $90.24M, although specific revenue growth data is currently not available. The gross profit is $35.71M. Operating income is noted at -$268.13M. Furthermore, the EBITDA is -$242.71M.

help
What is the market capitalization of REGENXBIO (RGNX)?

REGENXBIO (RGNX) has a market capitalization of $632.94M. The average daily trading volume is 580.33K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level